Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study.
Mahajan UM, Oehrle B, Goni E, Strobel O, Kaiser J, Grützmann R, Werner J, Friess H, Gress TM, Seufferlein TW, Uhl W, Will U, Neoptolemos JP, Wittel UA, Vornhülz M, Sirtl S, Beyer G, Regel I, Boeck S, Heinemann V, Frost F, Steveling A, Völzke H, Petersmann A, Nauck M, Weber E, Kamlage B, Lerch MM, Mayerle J; METAPAC trial investigators.
Mahajan UM, et al. Among authors: petersmann a.
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):634-647. doi: 10.1016/S2468-1253(25)00056-1. Epub 2025 May 16.
Lancet Gastroenterol Hepatol. 2025.
PMID: 40388948
Free article.
Clinical Trial.